Overview
We do not currently have sufficient capital resources to fund operations. To
stay in business and to continue the development of our products, we will need
to raise additional capital through public or private sales of our securities,
debt financing or short-term bank loans, or a combination of the foregoing. We
believe that if we can raise
to develop our business over the next approximately 15 months. At funding raised
that is significantly less than
our business over the same 15-month period, but funding at that level will delay
the development of our technology and business.
product pipeline is focused on developing and commercializing therapeutic
molecules for stroke. BXT-25 will be designed to be an injectable anti-necrosis
drug specifically designed to treat a person immediately after that person
suffers an ischemic stroke. The drug is designed to be injected intravenously to
travel to the lungs to pick up oxygen molecules to carry to the brain. Like a
red blood cell, the drug will cross the blood brain barrier, which is a
protective semi-permeable membrane allowing some material to cross but
preventing others from crossing. BXT-25 will be designed to diffuse oxygen into
the brain tissues. We expect the BXT-25 molecule to be 5,000 times smaller than
a red blood cell.
The Company plans to file a pre-investigational new drug application for
ProLectin for the treatment of mild to moderate Covid-19 patients. However, we
cannot provide any assurance that we will successfully initiate or complete
those planned trials and be able to initiate any other clinical trials for
ProLectin or any of our future drug candidates.
The accompanying consolidated financial statements have been prepared assuming
the Company will continue as a going concern. The Company has limited resources
and operating history. As described in Note 7 of the financial statements, the
Company currently has convertible loans outstanding at a total face value of
Company had an accumulated deficit of
accumulated deficit as at
The future of the Company is dependent upon its ability to obtain financing to
develop its new business opportunities and support the cost of the drug
development including clinical trials and regulatory submission to the FDA.
15 Covid-19 Effects
In
was reported to have surfaced in
throughout the World, and, on
declared Covid-19 to be a pandemic. In an effort to contain and mitigate the
spread of Covid-19, many countries, including
business closures and a substantial reduction in economic activity in countries
that have had significant outbreaks of Covid-19. Covid-19 may have a future
material impact on our results of operation with respect to product development
and clinical trials. However, significant uncertainty remains as to the
potential impact of the Covid-19 pandemic on our operations, and on the global
economy as a whole. It is currently not possible to predict how long the
pandemic will last or the time that it will take for economic activity to return
to prior levels. We do not yet know the full extent of any impact on our
business or our operations, however, we will continue to monitor the Covid-19
situation closely, and we intend to follow health and safety guidelines as they
evolve.
Management plans to seek additional capital through private placements and
public offerings of its Common Stock. There can be no assurance that the Company
will be successful in accomplishing its objectives. Without such additional
capital or the establishment of strategic relationships with established
pharmaceutical companies, the Company may be required to cease operations. These
conditions raise substantial doubt about the Company’s ability to continue as a
going concern. The financial statements do not include any adjustments relating
to the recoverability and classification of recorded assets, or the amounts of
and classification of liabilities that might be necessary in the event the
Company cannot continue operations.
Results of Operations
We are a clinical-stage pharmaceutical company. Historically,
engaged in formation, fund raising and identifying and consulting with the
scientific community regarding the development, formulation and testing of its
products.
Operating Expenses
Research and Development (R&D) expenses for the year ended
were
Our operations only started in the 4th quarter of 2020.
General and administrative (G&A) expenses for the year ended
were
The components of G&A expenses are as follows:
? Payroll and related expenses for the year endedDecember 31, 2021 were$1,391,379 , including payroll taxes and 401K benefits, as compared to$192,000 for the year endedDecember 31, 2020 . The difference was due the increase of the management's salaries to a market-based level. ? Costs for legal, accounting and other professional services for the year endedDecember 31, 2021 were$89,180 , as compared to$102,232 for the year endedDecember 31, 2020 . The decrease was due to reduced use of external corporate counsel. ? Sales and marketing expense for the year endedDecember 31, 2021 were$5,500 , as compared to$34,027 for the year endedDecember 31, 2020 . The decrease was due to limiting these expenditures in the current year as we're waiting for a go-ahead fromFINRA to re-enter the OTC-QB. ? The remaining miscellaneous G&A expenses totaled$131,751 for the year endedDecember 31, 2021 , as compared to$148,056 for the year endedDecember 31, 2020 .
Stock-based compensation mounted to
2021
1st quarter of 2021, in order to energize all collaborators in the development
and the regulatory pathway of the Company’s initial drug candidate.
16 Interest Expense and Amortization of Debt Discount and Premium
During the year ended
amortization of debt discount, as compared to,
additional paid-in capital, and
(including
2020
accrued for New Notes,
Old Notes), as compared to
the early payment of a convertible note and the default penalty of
the year ended
the fact that defaulted debt was re-negotiated and repurchased at face value.
Net Loss
The Company generated a net loss for the year ended
generated a net loss of
increased spending in Research and development, and that Managements salary was
increased to a market-based level. As counter balance the interest and
amortizations were radically reduced as described in the preceding paragraph.
Cash-Flows
Net cash used in operating activities was
years ended
Research and Development expenses starting in the 4th quarter of 2020, but
reduced by the conversion of debt to management converted to equity.
As at
year ended
legal fees.
Cash flows from financing activities were
ended
to convertible loans taken up in connection with the S-1 filing in late spring
2021.
Available cash was
2020
LIQUIDITY AND CAPITAL RESOURCES
As at
total liabilities of
consisted of
The equivalent numbers at
pre-paid expenses and
expenses. We had total liabilities of
liabilities, and which consisted of
expenses (of which
convertible loans. As a result of defaulting on the notes, the debt premium as
well as the debt discounts were fully amortized in 2020.
At
accumulated deficit of
total working capital of negative
to current cash on hand to be able to continue our business operations for
approximately the next 15 months.
Future Financing
We currently have an effective S-1, dated
raise an amount of
conventional sources and/or additional sales of stock in the future, we may be
forced to curtail or cease our operations. Even if we are able to continue our
operations, the failure to obtain financing could have a substantial adverse
effect on our business and financial results. In the future, we may be required
to seek additional capital by selling debt or equity securities, selling assets,
or otherwise be required to bring cash flows in balance when we approach a
condition of cash insufficiency. The sale of additional equity or debt
securities, if accomplished, may result in dilution to our then shareholders. We
provide no assurance that financing will be available in amounts or on terms
acceptable to us, or at all.
17 Contractual obligations
Our contractual obligations include convertible notes, with a face value of
described under Note 7 to the Financial Statements.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have, or are reasonably
likely to have, a current or future material effect on our consolidated
financial condition, results of operations, liquidity, capital expenditures or
capital resources.
CRITICAL ACCOUNTING POLICIES
In presenting our financial statements in conformity with generally accepted
accounting principles, we are required to make estimates and assumptions that
affect the amounts reported therein. Several of the estimates and assumptions we
are required to make relate to matters that are inherently uncertain as they
pertain to future events. However, events that are outside of our control cannot
be predicted and, as such, they cannot be contemplated in evaluating such
estimates and assumptions. If there is a significant unfavorable change to
current conditions, it could result in a material adverse impact to our results
of operations, financial position and liquidity. We believe that the estimates
and assumptions we used when preparing our financial statements were the most
appropriate at that time. Presented below are those accounting policies that we
believe require subjective and complex judgments that could potentially affect
reported results. However, the majority of our businesses operate in
environments where we pay a fee for a service performed, and therefore the
results of the majority of our recurring operations are recorded in our
financial statements using accounting policies that are not particularly
subjective, nor complex.
Stock Based Compensation
The Company has share-based compensation plans under which non-employees,
consultants and suppliers may be granted restricted stock, as well as options to
purchase shares of Company Common Stock at the fair market value at the time of
grant. Stock-based compensation cost is measured by the Company at the grant
date, based on the fair value of the award over the requisite service period.
The Company applies ASC 718 for options, Common Stock and other equity-based
grants to its employees and directors. ASC 718 requires measurement of all
employee equity-based payment awards using a grant date fair-value method and
recording of such expense in the consolidated financial statements over the
requisite service period. The fair value concepts have not changed significantly
in ASC 718; however, in adopting this standard, companies must choose among
alternative valuation models and amortization assumptions. After assessing
alternative valuation models and amortization assumptions, the Company will
continue using both the Black-Scholes valuation model and straight-line
amortization of compensation expense over the requisite service period for each
separately vesting portion of the grant.
© Edgar Online, source
https://www.marketscreener.com/quote/stock/BIOXYTRAN-INC-117540343/news/BIOXYTRAN-INC-Management-s-Discussion-and-Analysis-of-Financial-Condition-and-Results-of-Operation-40021708/